OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. To bridge the gap between research and patient care, these proceedings from a case-based CME satellite symposium at the 2009 San Antonio Breast Cancer Symposium utilize the perspectives of clinical investigators, in addition to the exchange among these individuals, to apply evidence-based concepts to routine practice. By providing access to the latest research developments and expert opinions on the disease, this activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of up-to-date clinical management strategies for patients with breast cancer.

LEARNING OBJECTIVES

• Use currently available tissue-based genomic assays to assist with therapeutic decision-making in the management of node-negative and node-positive early breast cancer.
• Apply the results of existing data and emerging research when selecting the optimal duration and sequence of endocrine therapy for appropriate patients.
• Optimize the treatment of HER2-overexpressing breast cancer through rational integration of existing and emerging HER2-directed agents.
• Communicate the benefit-risk profile of bevacizumab and its evidence-based therapeutic partners to appropriate patients with metastatic breast cancer.
• Incorporate the findings from recent clinical trials into the individualized selection and sequence of chemotherapy for patients with early or advanced triple-negative breast cancer.
• Counsel appropriately selected patients about the availability of ongoing clinical trial participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains audio and print components. To receive credit, the participant should review the CME information, listen to the MP3s or read the transcripts and complete the Post-test and Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Winer had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Chlebowski — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Paid Research: Lilly USA LLC; Speakers Bureau: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals Corporation. Dr Gianni — Advisory Committee: Abraxis BioScience, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi-Aventis, Wyeth; Consulting Agreement: Millennium Pharmaceuticals Inc. Dr O’Shaughnessy — Speakers Bureau: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Lilly USA LLC, Sanofi-Aventis. Dr Schneider — Advisory Committee: Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline; Paid Research: Genentech BioOncology.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.

Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2010
Expiration date: March 2011